In order to define response subgroups, the AML samples were separated into NK-AML and CK-AML and the NK-AML were grouped according to FLT3 status as well as sensitivity to combination treatment (FLT3wt-S, FLT3wt-R, FLT3ITD-S, FLT3ITD-R) (Figure 5F). Here, FLT3 is linked to acute myeloid leukemia.